iqvia weight loss drug prescriptions q3 2024 semaglutide tirzepatide Shows Superior Over in Phase 3 Trial The Dermatology Digest | The

According to the Pan American Health Organization (PAHO), over 62 million people in the Americas live with diabetes, while awareness campaigns have expanded screening and treatment access across more than 35 countries, supporting increased adoption of advanced therapies including GLP-1 drugs

The number of members on GLP-1s for weights loss is projected to grow significantly throughout the remainder of 2024 and into 2025

Semaglutide vs tirzepatide comparisons often focus on efficacy, but formulation differences matter equally

Clinical studies have demonstrated that sustained weight reductiontypically achieved through caloric restriction and increased physical activitycan lead to favourable changes in lipid parameters, including reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, alongside modest increases in high-density lipoprotein cholesterol (HDL-C)